Janssen, to close Hyangnam plant in Korea

Janssen Korea will close its Hyangnam plant in Hwaseong

Go through administrative procedures according to the technology transfer between Korea and Germany

Janssen Korea‘s factory in Hyangnam

With the withdrawal of the Hyangnam factory this year, Janssen Korea is reorganizing its domestic product lineup of Tylenol and Ultracet The production of Tylenol 8 hours ER and Ultracet is undergoing a transition or shutdown procedure.

 

According to the MFDS on the 8th, all Ultracet products, an analgesic combination drug containing Tramadol-Acetaminophen, which were produced in the Hyangnam factory, were all converted for export.

 

Accordingly, Ultracet produced at the Hyangnam Plant will soon end its insurance benefits.

 

Ultracet is largely divided into fast-acting tablet typed Ultracet, and sustained-release tablet typed Ultracet ER.

 

It is also divided into Ultracet, Ultracet Semi, Ultracet ER, and Ultracet ER Semi according to the size (the dosage).

 

Janssen Korea’s Ultracet and Ultracet Semi, which were previously produced at the Hyangnam factory, have been converted into export products within the last year.

 

An export item is a product used only for export, not sold in the domestic market.

 

When switching to export, insurance benefits are removed, and insurance claims can be made for six months to close inventory.

 

It will not be sold in the domestic market.

 

Ultracet was converted to an imported product produced at factories in Canada and Italy last May.

 

Janssen of Korea recently sent an official letter to the distribution industry about Ultracet Semi, saying that the provider will be changed to Handok, and that it will be available in June after an administrative procedure.

 

Accordingly, only Ultracet ER and Ultracet ER Semi are produced at Hyangnam Plant.

 

Ultracet ER has a higher sales performance than Ultracet.

 

Based on IQVIA, the cumulative sales for the first half of last year show that Ultracet ER was ₩4.7 billion, Ultracet ER Semi was ₩4.2 billion, Ultracet was ₩2.4 billion, and Ultracet Semi was ₩1.1 billion.

 

As the Hyangnam plant operates until this year and the sale process to Whanin Pharm is completed by March next year, the manufacturer of Ultracet ER products is also expected to change.

 

Janssen Korea is also promoting technology transfer to Handok.

 

Janssen recently sent an official letter to the distributor, saying that it will supply Tylenol 8 hours ER 325mg by April and withdraw.

 

Tylenol 8 hours ER 325mg will be terminated and only Tylenol 650mg will be distributed.

 

Based on IQVIA, the cumulative sales of Tylenol in the first half of last year were ₩12.5 billion, and Tylenol 8 hours ER 325mg was ₩5.7 billion.

 

In August of last year, Johnson & Johnson Korea received a license for Children's Tylenol 160mg from Canada.

 

However, it is not yet known what will happen to Tylenol produced in Korea after the Hyangnam plant is closed.